ArticleThe Lancet. Oncology2024

CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.

Anna-Maria Lazaratos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.